DuPont is pumping up its slumping health business with a new life sciences research facility near Wilmington, Del. and a new pharmaceuticals process development facility in Deepwater, NJ. A "significant portion" of the firm's Biomedical Product capital expenditures for the years of $87 mil. (v. $86 mil. in 1982) was for work on these facilities, DuPont said. DuPont is banking on results of these two projects to boost its Biomedical Products division, which in 1983 recorded flat sales of $1.1 bil. Operating earnings for the business segment dropped from $130 mil. to $86 mil., according to the company's annual report for the year. While DuPont acknowledges that its pharmaceutical business "is not large at present," the company said it is gearing up for "aggressive research and licensing programs [which] focus on the goal of becoming a major contributor worldwide." To augment that effort, the company has established a Research Advisory Board of scientists primarily from outside DuPont, under the chairmanship of Howard Johnson, honorary chairman of MIT and a company director. DuPont's drug research "is aimed at products in the treatment of cancer, cardiovascular problems, pain, infection diseases and metabolic disorders such as arthritis and diabetes," the firm said. The biomedical business operating earnings decline "reflects lower income for medical X-ray film due to higher silver costs and the continuing adverse effects of the strong U.S. dollar," DuPont said. "Income for clinical systems remained" close to 1982 levels "despite increased competition and slower market growth, reflecting strong marketing efforts and continuing productivity gains in manufacturing." DuPont's $220 mil. clinical chemistry business represents 10% of the firm's estimate of a total $2.2 bil. clinical chemistry market, DuPont reported, adding that t "produces 40% of all radioactive materials used for diagnosis in the U.S. and more than 10% of those used in Europe." The company stated that it is now the "second largest mfr. of X-ray and medical imaging films in the world," behind traditional leader Kodak. In the diagnostics area, DuPont has expanded its aca discrete clinical analyzer line with eight new tests in the past few months. New England Nuclear has added two new tests, the company reported, to aid in the diagnosis of cancer.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.
